Genetic mutations in KRAS, NRAS, and BRAF were commonly implicated in the development of both melanoma and CRC, while mutations in CDKN2A and BRCA2 were specifically significant in melanoma. This evidence concerns the gene NRAS and colorectal carcinoma.